Advisory board urges expanded access to hepatitis C drugs

Cancer Moonshot
December 23, 2016
Multiple sclerosis drug ‘a landmark’
December 26, 2016
Show all

Advisory board urges expanded access to hepatitis C drugs

Vermont struggles to pay for expensive hepatitis C medications.

An advisory board says the state should make it easier for Vermont’s Medicaid patients to get access to expensive prescription drugs that treat hepatitis C.

The Medicaid Drug Utilization Review Board, an advisory panel, voted Dec. 6 to lift certain restrictions that make it harder or impossible for some Medicaid patients with the disease to get specialty drugs.

The Department of Vermont Health Access, which administers Medicaid, will need to decide whether to accept the board’s changes. The department has historically set strict restrictions on the drugs because of their high cost.

Steven Costantino, the commissioner of the Department of Vermont Health Access, said in February the cost of the drugs is “a critical concern” to the state from a financial perspective and “kind of an ethical dilemma” for people running state Medicaid programs.

Read full article: Advisory board urges expanded access to hepatitis C drugs – VTDigger

Read Full Article: Advisory board urges expanded access to hepatitis C drugs – VTDigger

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.